Next Steps for Efficacy Evaluation in Clinical Trials of COVID-19 Vaccines

References

[[1]] Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Plotkin’s vaccines. 7th ed. Philadelphia: Elsevier; 2018.

[[2]] Preiss S, Garçon N, Cunningham AL, Strugnell R, Friedland LR. Vaccine provision: delivering sustained & widespread use. Vaccine 2016;34(52):6665–71.

[[3]] Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 2021;384 (5):403–16.

[[4]] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020;383 (27):2603–15.

[[5]] Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARSCoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397(10269):99–111.

[[6]] sputnikvaccine.com [Internet]. Moscow: The Gamaleya National Center; 2020 [cited 2020 Dec 16]. Available from: https://sputnikvaccine.com/ newsroom/pressreleases/the-cost-of-one-dose-will-be-less-than-10-for-international-markets/.

[[7]] www.novavax.com [Internet]. Gaithersburg: Novavax; 2021 [cited 2021 Jan 29]. Available from: https://www.novavax.com/covid-19-coronavirusvaccine-candidate-updates.

[[8]] www.janssen.com [Internet]. Berne: Janssen Global Services; 2021 [cited 2021 Jan 30]. Available from: https://www.janssen.com/johnson-johnson-announcessingle-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints.

[[9]] www.who.int [Internet]. Geneva: WHO; 2021 [cited 2021 Jan 31]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid19-candidate-vaccines.

[[10]] Wolf J, Bruno S, Eichberg M, Jannat R, Rudo S, VanRheenen S, et al. Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens. NPJ Vaccines 2020;5(1):51.

[[11]] Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021;397(10275):671–81.

[[12]] Rid A, Lipsitch M, Miller FG. The ethics of continuing placebo in SARS-CoV-2 vaccine trials. JAMA 2021;325(3):219–20.

[[13]] Rid A, Saxena A, Baqui AH, Bhan A, Bines J, Bouesseau MC, et al. Placebo use in vaccine trials: recommendations of a WHO expert panel. Vaccine 2014;32 (37):4708–12.

[[14]] Nolan SJ, Hambleton I, Dwan K, Scherag A. The use and reporting of the crossover study design in clinical trials and systematic reviews: a systematic assessment. PLoS ONE 2016;11(7):e0159014.

[[15]] Louis TA, Lavori PW, Bailar JC, Polansky M. Crossover and self-controlled designs in clinical research. N Engl J Med 1984;310(1):24–31.

[[16]] www.fda.gov [Internet].Washington, DC: Administration USFDA; 2020 [cited 2021 Jan 30]. Available from: https://www.fda.gov/advisory-committees/advisorycommittee-calendar/vaccines-and-related-biological-products-advisorycommittee-december-10-2020-meeting-announcement#event-materials.

[[17]] Sekhar A, Kang G. Human challenge trials in vaccine development. Semin Immunol 2020;50:101429.

[[18]] Bambery B, Selgelid M, Weijer C, Savulescu J, Pollard AJ. Ethical criteria for human challenge studies in infectious diseases. Public Health Ethics 2016; 9(1):92–103.

[[19]] Cornwall W. New challenges emerge for planned human challenge trials. Science 2020;370(6521):1150.

[[20]] Donken R, de Melker HE, Rots NY, Berbers G, Knol MJ. Comparing vaccines: a systematic review of the use of the non-inferiority margin in vaccine trials. Vaccine 2015;33(12):1426–32.

[[21]] Wangge G, Klungel OH, Roes KCB, de Boer A, Hoes AW, Knol MJ, et al. Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: a systematic review. PLoS ONE 2010;5(10):e13550.

[[22]] Joffe S. Evaluating SARS-CoV-2 vaccines after emergency use authorization or licensing of initial candidate vaccines. JAMA 2021;325(3):221–2.

[[23]] Foppa IM, Haber M, Ferdinands JM, Shay DK. The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine 2013;31(30):3104–9.

[[24]] Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 2013;31(17):2165–8.

[[25]] Foppa IM, Ferdinands JM, Chaves SS, Haber MJ, Reynolds SB, Flannery B, et al. The case test-negative design for studies of the effectiveness of influenza vaccine in inpatient settings. Int J Epidemiol 2016;45(6):2052–9.

[[26]] Halloran ME, Struchiner CJ, Longini IM Jr. Study designs for evaluating different efficacy and effectiveness aspects of vaccines. Am J Epidemiol 1997;146(10):789–803.

[[27]] Hemming K, Haines TP, Chilton PJ, Girling AJ, Lilford RJ. The stepped wedge cluster randomised trial: rationale, design, analysis, and reporting. BMJ 2015;350:h391.

[[28]] Brown CA, Lilford RJ. The stepped wedge trial design: a systematic review. BMC Med Res Methodol 2006;6(1):54.

[[29]] Krause PR, Fleming TR, Longini IM, Peto R, Beral V, Bhargava B, et al. Placebocontrolled trials of COVID-19 vaccines—why we still need them. N Engl J Med 2021;384(2):e2.

[[30]] Wendler D, Ochoa J, Millum J, Grady C, Taylor HA. COVID-19 vaccine trial ethics once we have efficacious vaccines. Science 2020;370(6522):1277–9.

[[31]] Singh JA, Upshur REG. The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials. Lancet Infect Dis 2021;21(4):e103–9.

[[32]] Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis 2021;21 (2):e26–35.

[[33]] Plotkin SA, Gilbert PB. Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis 2012;54(11):1615–7.

[[34]] Collins R, Bowman L, Landray M, Peto R. The magic of randomization versus the myth of real-world evidence. N Engl J Med 2020;382(7):674–8.

[[35]] Fleming TR, Ellenberg SS. Evaluating interventions for Ebola: the need for randomized trials. Clin Trials 2016;13(1):6–9.

[[36]] Lipsitch M, Dean NE. Understanding COVID-19 vaccine efficacy. Science 2020;370(6518):763–5.

[[37]] Cohen J, Kupferschmidt K. Ebola vaccine trials raise ethical issues. Science 2014;346(6207):289–90.

[[38]] Lurie N, Sharfstein JM, Goodman JL. The development of COVID-19 vaccines: safeguards needed. JAMA 2020;324(5):439–40.